Pulmonary Procoagulant and Innate Immune Responses in Critically Ill COVID-19 Patients
Esther J. Nossent(Amsterdam UMC Location Vrije Universiteit Amsterdam), Tom van der Poll(Amsterdam Neuroscience), Alex R. Schuurman(Amsterdam Neuroscience), Heder de Vries(Amsterdam University Medical Centers), Anton Vonk Noordegraaf(Amsterdam University Medical Centers), Siebe G. Blok, René Lutter(Amsterdam Neuroscience), JanWillem Duitman(Amsterdam Neuroscience), Leo Heunks(Radboud University Nijmegen), Harm Jan Bogaard(Amsterdam UMC Location Vrije Universiteit Amsterdam), Ilse Jongerius(Sanquin), Anno Saris(Leiden University Medical Center), Lilian J. Meijboom(Amsterdam University Medical Centers), Tom D. Y. Reijnders(Amsterdam University Medical Centers)
Cited by 46
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Sepsis: a roadmap for future research
|The Lancet Infectious Diseases|2015|1k